Case Study · TPP
How AI Powered TPP Testing Called the Market Before the Research Confirmed It
At a Glance
The Business Challenge
A global oncology portfolio team was advancing three pipeline assets into a crowded, fast-evolving treatment category, each with a distinct — and still-blinded — target product profile. Before committing to a full multi-market fielding program, the team needed an early, credible read on how physicians would actually react to each profile and how adoption might vary across specialties. The stakes were real: a costly, multi-market research program was riding on getting the right questions in front of the right physicians the first time.
Context
- Three blinded target product profiles advancing within the same fast-evolving oncology category
- A full multi-market primary fielding program had not yet been committed
- Prior primary research existed across several earlier studies but had not been synthesized into a forward-looking view
- Portfolio decisions carried significant cost and timeline risk if the wrong questions were fielded
- No physician-facing data yet existed comparing how the three profiles would be received
The S+R Approach
Rather than start from a blank page, S+R used clients’ prior primary research, then added our Stellaverse™, a highly curated view of the entire therapeutic area, spanning physician demand, opportunity assessment, and market context — alongside broader clinical, competitive, and digital-conversation intelligence — to answer the question in-depth with credentialed data to enable client commercial teams to make a very confident go-decision. Stella used this foundation to generate structured, forward-looking hypotheses on how physicians would evaluate each of the three blinded target product profiles against each other and the competitive landscape, including where specialty-level differences in physician engagement might shape adoption. This was synthesis and prediction only — no new primary interviews had yet been fielded. The approach let the team pressure-test its portfolio thinking in days rather than the months a traditional qualitative-first design would have required, while preserving the option to validate directionally with real physicians before finalizing strategy.
Research Objectives
-
01
Determine how physicians would likely differentiate among the three blinded target product profiles
-
02
Identify which patient scenarios and treatment contexts each profile was best positioned to address
-
03
Assess whether specialty-level differences in physician engagement would shape future adoption patterns
Insights Delivered
Key Findings
-
The AI-generated synthesis produced clear, differentiated hypotheses across all three target product profiles
-
Distinct adoption patterns emerged among the profiles, shaped by differences in clinical and practical positioning
-
Specialty-level differences in physician engagement surfaced as a meaningful factor in future adoption
-
The analysis identified where each profile was likely to compete most directly against existing treatment approaches
-
When benchmarked against the primary research that followed, the AI-generated hypotheses scored approximately 4.5 out of 5 on directional accuracy
Strategic Impact
When the client subsequently fielded independent qualitative and quantitative research with physicians across multiple global markets, the AI-generated hypotheses held up — scoring approximately 4.5 out of 5 in a post-project accuracy comparison against the primary findings. That gave the team confidence in its portfolio thesis before a single new interview had taken place. Rather than redirecting the client’s strategy, the primary research largely confirmed and refined it, validating that the AI-powered synthesis phase had given the team a reliable, quantifiably accurate head start on planning, resourcing, and investment-committee-readiness conversations.
Key Deliverables
-
Stellaverse-powered TPP prediction model synthesizing the client's existing primary research
-
Forward-looking adoption hypotheses across three blinded target product profiles
-
Specialty-level physician engagement analysis
-
A directional validation checkpoint ahead of primary fielding
TPP testing decisions carry real portfolio risk when they happen too late or too slowly. Talk to us about how AI-powered synthesis can give your team a validated head start before you commit to a full fielding program.
Stay Informed
Contact Us
Let's discuss how we can accelerate your strategic decisions.